TY  - CHAP
M1  - Book, Section
TI  - Chapter 83. Blood and Blood Component Therapy
A1  - Welsby, Ian J.
A1  - Hathaway, Jessica A.
A2  - Longnecker, David E.
A2  - Brown, David L.
A2  - Newman, Mark F.
A2  - Zapol, Warren M.
PY  - 2012
T2  - Anesthesiology, 2e
AB  - ABO  compatibility  remains  the  major  safety  consideration  for  blood  transfusion.  Clerical  errors  of  patient  identification  and  sample  labeling  remain  the  primary  cause  of  mistransfusion  of  ABO-incompatible  units.Prestorage  leukoreduction  of  cellular  blood  products  has  greatly  reduced,  but  not  eliminated,  the  incidence  of  febrile  reactions,  transfusion-related  immunosuppression,  and  cytomegalovirus  transmission,  and  has  led  to  improved  outcomes  in  surgical  patients  compared  to  the  use  of  nonleukoreduced  products.Redirecting  blood  from  female  donors  away  from  transfusable  plasma  products  appears  to  have  reduced  the  incidence  of  TRALI  mediated  by  leucocyte  reactive  antibodies.  However,  some  plasma  from  female  donors  remains  in  platelet  and  red  blood  cell  products.International  travel  and  associated  exposure  to  pathogens  not  addressed  by  existing  screening  mechanisms  will  increasingly  limit  suitable  blood  donors.  These  and  other  pressures  on  the  blood  supply  make  imperative  strategies  all  the  more  important  for  blood  conservation  and  promotion  of  bloodless  surgical  techniques.  
SN  - 
PB  - The McGraw-Hill Companies
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessanesthesiology.mhmedical.com/content.aspx?aid=56654919
ER  -